<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471883</url>
  </required_header>
  <id_info>
    <org_study_id>00543186</org_study_id>
    <nct_id>NCT04471883</nct_id>
  </id_info>
  <brief_title>LATAM Bif Registry</brief_title>
  <official_title>Latin American Registry of Percutaneous Interventions in Coronary Bifurcations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LATAM Bifurcation Club</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LATAM Bifurcation Club</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LATAM Bif Registy is an international and prospective registry of percutaneous coronary
      interventions (PCI) in coronary bifurcation lesions. The main goal of the study is to
      investigate the current state and long-term outcomes of PCI in this complex subset of
      coronary lesions in Latin America.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Bifurcation Lesion</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary interventions</intervention_name>
    <description>Percutaneous coronary interventions in coronary bifurcation lesions</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients â‰¥18 years of age, who have at least one significant lesion in a coronary
        bifurcation on diagnostic cinecoronary angiography and who are candidates to treatment with
        PCI, regardless of the dedicated-technique used. Those patients who present lesions
        involving vessels &lt;2 mm by visual estimation and those who refuse to be included in the
        registry will be excluded.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Any type of bifurcation lesion

          -  Side-branch reference diameter &gt;= 2 mm

        Exclusion Criteria:

          -  Protected left main disease in patients with previous CABG

          -  Patients who refuse to be included in the registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Marcelo A. Abud, M.D</last_name>
    <phone>54 11 33085742</phone>
    <email>latambif@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucio T. Padilla, M.D</last_name>
    <email>latambif@gmail.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

